1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gemina Laboratories Ltd.

Gemina Laboratories Ltd.

GLAB.CN
Gemina Laboratories Ltd.CA flagCanadian Securities Exchange
0.06
CAD
- -
- -
4.59MMarket Cap
Gemina Laboratories Ltd.
GLAB.CN
(Canadian Securities Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.1
-0.1
-0.07
-0.06
-0.05
Basic EPS, GAAP
- -
-0.08
-0.08
-0.05
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.06
-0.08
-0.12
-0.12
Book Value per Share
- -
0.02
- -
-0.02
-0.06
-0.06
Tangible Book Value per Share
- -
48
60
72
74
75
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-35,059.93
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-5
-6
-5
-4
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-36,846.4
Profit Margin (%)
- -
1
-1
-3
-6
-5
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
- -
-2
-4
-4
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-4,444.43
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
77
Market Capitalization
28
40
76

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
6
Payables & Accruals
4
5
5
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
179.78%
Free Cash Flow
- -
- -
-60.4%
Net Income, GAAP
- -
- -
-21.91%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
- -
-0.07
2025
-0.01
-0.01
-0.01
- -
-0.06
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Mymetics Corp. (MYMXE)
Arcutis Biotherapeutics, Inc. (ARQT)
Aelis Farma S.A. (AELIS.PA)
IMV Inc. (IMV)
Abcam plc (ABC.L)
Regulus Therapeutics Inc. (RGLS)
Business
Gemina Laboratories Ltd. (CSE:GLAB) operates as a Canada-based biotechnology company focused on the research, development, and commercialization of in-vitro diagnostics and biosensor technologies for point-of-care testing of respiratory pathogens and other diseases. Founded in 2017 and headquartered in Burnaby, British Columbia, the company offers proprietary surface functionalization chemistries under the GeminaChem platform, including dual affinity binding mechanisms, gold binding proteins, and cellulose binding proteins; point-of-care lateral flow diagnostic products such as LEGIO X COVID-19 rapid antigen test, LEGIO X (also known as LEGIO XI) Influenza A/B multiplex test, and products in development for respiratory syncytial virus and tuberculosis; and R&D services through its strategic partner RAPIvD Limited. Gemina Laboratories primarily serves the global diagnostics industry, with technologies applicable to respiratory infections, women's health, cardiology, and central lab testing, targeting manufacturers of lateral flow assays via licensing agreements. In April 2024, the company signed its first strategic license agreement with a major global diagnostics firm to develop and commercialize products using its IP, enabling up to 75% antibody cost reductions; issued its first commercial invoice in June 2024, with revenues ramping in 2025; and advanced discussions with four additional diagnostics companies while pursuing facility expansions for protein production.